Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by ...
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...
The FDA's decision last year to make complete response letters public provides new insight into why therapies sometimes fail ...
The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head ...
After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. But analysts don’t expect much relief, no matter who ...
After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition agreement involving Ouro Medicines, Galapagos now has a new moniker.
New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...
(Image source: https://gisaid.org/rsv-subtypes-dashboard) ...
The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the study could in fact support the cell ...
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve ...
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder ...
The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results